PUBLICATIONS & ABSTRACTS: CLINICAL EVIDENCE
100s of extensive peer reviewed publications and studies utilizing MammaPrint + BluePrint have observed benefits from treatment in the following areas of clinical utility:
Scientific evidence for clinical utility.
By continually expanding and strengthening our database of proven research including 20+ years of clinical validation and 200+ research collaborations, we have gained widespread trust in the precision, accuracy and quality of our MammaPrintยฎ and BluePrintยฎ test suite.
Evidence
Performance Characteristics of the MammaPrintยฎ Breast Cancer Diagnostic Gene Signature
PUBLICATION: PERSONALIZED MEDICINE VOL. 10, NO. 8 | 17 Oct 2013 https://doi.org/10.2217/pme.13.88 AUTHORS: Leonie J.M. Delahaye, Diederik Wehkamp, Arno N. Floore, Rene Bernards, Laura J. vanโt Veer & Annuska M. Glas SUMMARY: Here we study these performance characteristics of the MammaPrintยฎ (Agendia NV, Amsterdam, The Netherlands) 70-gene signature using the Read More
Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics
PUBLICATION: Breast Cancer Res Treat (2013) 140:475โ484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Floris H. Groenendijk, Wilbert Zwart, Arno Floore, Stephanie Akbari, Rene Bernards ABSTRACT: It is well established that only estrogen receptor (ER)-positive tumors benefit from hormonal therapies. We hypothesized that a subgroup of breast cancer patients expresses estrogen receptor ฮฑ (ERฮฑ), Read More
Potential Impact of the 70-gene Signature in the Choice of Adjuvant Systemic Treatment for ER Positive, HER2 Negative Tumors: a Single Institution Experience
PUBLICATION: Breast. 2013 Aug;22(4):419-24. doi: 10.1016/j.breast.2013.03.013. Epub 2013 May 3. AUTHORS: Torrisi R., Garcia-Etienne C.A., Losurdo A., Morenghi E., Di Tommaso L., Gatzemeier W., Sagona A., Fernandes B., Rossetti C., Eboli M., Rubino A., Barbieri E., Andreoli C., Orefice S., Gandini C., Rota S., Zuradelli M., Masci G., Santoro A., Read More
MammaPrint Pre-Screen Algorithm (MPA) Reduces Chemotherapy in Patients with Early-Stage Breast Cancer
PUBLICATION: S Afr Med J. 2013 Jul 3;103(8):522-6. doi: 10.7196/samj.7223. AUTHORS: Grant K.A., Apffelstaedt J.P., Wright C.A., Myburgh E., Pienaar R., De Klerk M., Kotze M.J. SUMMARY: The 70-gene profile classifies approximately 40% of early-stage breast cancer patients as low-risk compared with 15% using conventional criteria. In comparison, more than Read More
Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients
PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retรจl V.P., Groothuis-Oudshoorn C.G., Aaronson N.K., Brewer N.T., Rutgers E.J., van Harten W.H. SUMMARY: Based on MINDACT: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Read more: Retรจl Read More
Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
PUBLICATION:ย Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS:ย Glรผck S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. ABSTRACT: The aim of this study was to analyze the correlation between the pathologic complete response (pCR) rate after neoadjuvant chemotherapy and long-term outcome (distant metastases-free survival [DMFS]) in Read More
Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses
PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. AUTHORS: Rouzier R., Pronzato P., Chรฉreau E., Carlson J., Hunt B., Valentine W.J. SUMMARY: Systematic Review: The review identified 29 publications that reported evaluations of two assays: Oncotype DX(ยฎ) and MammaPrint. Studies of both tests provided evidence Read More
